Adverse events following vaccination with 23-valent pneumococcal polysaccharide vaccine among≥18-year-old individuals with human immunodeficiency virus infection:an observational study in Xihu district of Hangzhou city
Adverse events following vaccination with 23-valent pneumococcal polysaccharide vaccine among≥18-year-old individuals with human immunodeficiency virus infection:an observational study in Xihu district of Hangzhou city
Objective To determine incidences of adverse events following vaccination with 23-valent pneumococcal polysaccharide vaccine(PPV23)in ≥ 18-year-old individuals living with human immunodeficiency virus(HIV).Methods We enrolled HIV-infected adults over 18 years of age from vaccination clinics in Xihu district of Hangzhou city and followed them up for adverse events 0-28 days after receiving one dose of PPV23 to determine incidences.Results The overall incidence of adverse events 0-28 days after one dose of PPV23 vaccination was 32.89％(148/450),with local and systemic adverse event rates of 31.33％(141 cases)and 2.22％(10 cases).Incidences for injection-site pain,redness,and swelling were 24.89％(112 cases),7.33％(33 cases),and 10.00％(45 cases).Incidences for fever and dizziness were 2.00％(9 cases)and 0.22％(1 case).No serious adverse events were reported.Conclusion The incidence of adverse events following PPV23 vaccination of people≥18 years of age living with HIV was less than expected,and symptoms of adverse events were mild.
维普
万方数据